Interplay between cyclooxygenase‑2 and microRNAs in cancer (Review).
cyclooxygenase‑2
microRNAs
therapeutic target
cyclooxygenase‑2 inhibitors
cancer
inflammation
Journal
Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
10
11
2020
accepted:
23
02
2021
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
11
5
2021
Statut:
ppublish
Résumé
Tumor‑associated inflammation and aberrantly expressed biomarkers have been demonstrated to play crucial roles in the cancer microenvironment. Cyclooxygenase‑2 (COX‑2), a prominent inflammatory factor, is highly expressed in tumor cells and contributes to tumor growth, recurrence and metastasis. Overexpression of COX‑2 may occur at both transcriptional and post‑transcriptional levels. Thus, an improved understanding of the regulatory mechanisms of COX‑2 can facilitate the development of novel antitumor therapies. MicroRNAs (miRNAs) are a group of small non‑coding RNAs that act as translation repressors of target mRNAs, and play vital roles in regulating cancer development and progression. The present review discusses the association between miRNAs and COX‑2 expression in different types of cancer. Understanding the regulatory role of miRNAs in COX‑2 post‑transcription can provide novel insight for suppressing COX‑2 expression via gene silencing mechanisms, which offer new perspectives and future directions for the development of novel COX‑2 selective inhibitors based on miRNAs.
Identifiants
pubmed: 33760116
doi: 10.3892/mmr.2021.11986
pii: 347
pmc: PMC7974460
doi:
pii:
Substances chimiques
Cyclooxygenase 2 Inhibitors
0
MicroRNAs
0
Cyclooxygenase 2
EC 1.14.99.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Oncogene. 2008 Dec 4;27(53):6729-37
pubmed: 18794809
N Engl J Med. 2016 Dec 29;375(26):2519-29
pubmed: 27959716
Pathol Res Pract. 2018 Jun;214(6):907-913
pubmed: 29559247
Cancer Metastasis Rev. 2018 Mar;37(1):17-32
pubmed: 29327093
PLoS One. 2015 Nov 10;10(11):e0140642
pubmed: 26556718
Biomed Pharmacother. 2018 Oct;106:35-42
pubmed: 29945115
Cancer Prev Res (Phila). 2011 Jul;4(7):1073-83
pubmed: 21430074
J Biomed Biotechnol. 2010;2010:828045
pubmed: 20625420
J Exp Clin Cancer Res. 2010 Sep 01;29:119
pubmed: 20809941
J Biol Chem. 2015 May 29;290(22):14245-66
pubmed: 25907560
Exp Ther Med. 2018 Mar;15(3):3088-3095
pubmed: 29456712
RNA Biol. 2015;12(4):457-77
pubmed: 25757558
Gastroenterology. 2009 Oct;137(4):1358-66.e1-3
pubmed: 19549529
Am J Transl Res. 2020 Mar 15;12(3):1096-1113
pubmed: 32269737
Anticancer Res. 2016 May;36(5):2073-83
pubmed: 27127107
Anticancer Res. 2017 Jun;37(6):2913-2918
pubmed: 28551628
J Exp Clin Cancer Res. 2018 Oct 12;37(1):248
pubmed: 30314513
World J Gastroenterol. 2013;19(43):7758-65
pubmed: 24616567
Cancer Lett. 2009 Nov 28;285(2):116-26
pubmed: 19464788
Asian Pac J Cancer Prev. 2014;15(21):9185-90
pubmed: 25422199
Cancer. 2019 Apr 15;125(8):1221-1227
pubmed: 30747998
Mol Cell. 2017 Apr 20;66(2):258-269.e5
pubmed: 28431232
FEBS J. 2012 Nov;279(22):4201-12
pubmed: 23013439
Asian Pac J Cancer Prev. 2015;16(2):627-33
pubmed: 25684498
Nat Biotechnol. 2003 Jun;21(6):635-7
pubmed: 12754523
Int J Mol Sci. 2017 Dec 05;18(12):
pubmed: 29206174
Cancers (Basel). 2019 Dec 07;11(12):
pubmed: 31817839
Biomed Pharmacother. 2018 Feb;98:793-800
pubmed: 29571248
Br J Cancer. 2012 Jan 17;106(2):366-74
pubmed: 22108519
Oncol Rep. 2012 Jun;27(6):1873-8
pubmed: 22469973
Oncotarget. 2018 Jan 3;9(9):8415-8426
pubmed: 29492204
Thorac Cancer. 2015 Nov;6(6):778-84
pubmed: 26557918
Mol Carcinog. 2020 Mar;59(3):265-280
pubmed: 31867776
Anal Chem. 2018 Apr 17;90(8):5187-5193
pubmed: 29587478
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Cancer Lett. 2020 Feb 1;470:126-133
pubmed: 31730903
Asian Pac J Cancer Prev. 2011;12(4):929-33
pubmed: 21790228
J Gastroenterol Hepatol. 2020 Jan;35(1):157-164
pubmed: 31222831
Cell Physiol Biochem. 2018;48(6):2493-2502
pubmed: 30121641
Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8
pubmed: 17991681
Biol Open. 2017 Mar 15;6(3):311-316
pubmed: 27895048
Semin Liver Dis. 2019 Feb;39(1):26-42
pubmed: 30809789
Oncotarget. 2016 Jun 21;7(25):38626-38637
pubmed: 27232941
J Cell Biochem. 2018 Feb;119(2):1755-1766
pubmed: 28786533
Sci Rep. 2017 Jul 20;7(1):6074
pubmed: 28729694
Life Sci. 2020 Oct 1;258:118110
pubmed: 32698074
PLoS One. 2012;7(11):e50935
pubmed: 23226427
Sci Rep. 2017 Aug 2;7(1):7113
pubmed: 28769030
Dig Dis Sci. 2020 Jul;65(7):1982-1991
pubmed: 31781909
Mol Ther Nucleic Acids. 2020 Jun 5;20:606-620
pubmed: 32348938
Oncol Lett. 2020 Mar;19(3):1824-1830
pubmed: 32194676
Int J Oncol. 2013 Feb;42(2):776-84
pubmed: 23254909
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Int J Cancer. 2013 Apr 15;132(8):1751-60
pubmed: 23001726
Am J Pathol. 2018 Mar;188(3):559-573
pubmed: 29429545
Curr Opin Ophthalmol. 2010 May;21(3):203-12
pubmed: 20224400
Oncotarget. 2010 Dec;1(8):710-20
pubmed: 21321380
J Ovarian Res. 2018 Feb 27;11(1):17
pubmed: 29482584
Exp Mol Med. 2020 Apr;52(4):538-547
pubmed: 32235869
Mol Cell Biochem. 2018 Nov;448(1-2):61-69
pubmed: 29404887
Oncology. 2009;77(1):12-21
pubmed: 19439999
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
J Clin Invest. 2019 Jul 29;129(9):3521-3523
pubmed: 31355777
Int J Mol Med. 2019 Aug;44(2):683-693
pubmed: 31198976
Sci Rep. 2018 Jan 10;8(1):327
pubmed: 29321644
Medicine (Baltimore). 2020 Aug 28;99(35):e22045
pubmed: 32871962
Oncotarget. 2017 Mar 14;8(11):17981-17994
pubmed: 28152501
Medicine (Baltimore). 2018 Aug;97(35):e11859
pubmed: 30170377
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Nat Commun. 2019 May 20;10(1):2225
pubmed: 31110179
Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):409-19
pubmed: 16831307
Mol Cancer Res. 2015 Jun;13(6):1022-33
pubmed: 25733698
J Cancer Res Clin Oncol. 2020 Jan;146(1):19-31
pubmed: 31734836
Front Oncol. 2020 Mar 05;10:233
pubmed: 32195180
Cancer Immunol Res. 2017 Aug;5(8):695-709
pubmed: 28765120
Gene. 2018 Jun 5;658:63-69
pubmed: 29524580
Oncotarget. 2019 Aug 27;10(50):5168-5180
pubmed: 31497247
J Cell Physiol. 2019 May;234(5):5683-5699
pubmed: 30341914
FEBS Lett. 2014 Aug 25;588(17):3274-81
pubmed: 25064845
Med Oncol. 2011 Sep;28(3):796-803
pubmed: 20401641
J Cancer Res Ther. 2019;15(2):278-285
pubmed: 30964098
Oncogene. 2017 Jun 1;36(22):3137-3148
pubmed: 27941877
Int J Clin Exp Med. 2013 Apr 12;6(4):239-51
pubmed: 23641300
Cancers (Basel). 2019 Oct 11;11(10):
pubmed: 31614548
Toxicol Lett. 2014 Apr 21;226(2):107-16
pubmed: 24472607
World J Gastroenterol. 2014 Sep 7;20(33):11727-35
pubmed: 25206276
J Invest Dermatol. 2020 Aug;140(8):1665-1669.e5
pubmed: 31981577
Life Sci. 2020 Jan 1;240:117077
pubmed: 31751586
Oncogene. 2007 Sep 13;26(42):6133-40
pubmed: 17404574
Onco Targets Ther. 2016 Jul 26;9:4629-37
pubmed: 27555783
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2017 Sep 22;8(52):89802-89810
pubmed: 29163789
Brain Behav Immun. 2016 Nov;58:91-98
pubmed: 27235931
Cytokine. 2019 Jun;118:144-159
pubmed: 29580751
Chem Biol Interact. 2017 Nov 1;277:33-42
pubmed: 28844858
J Cell Biochem. 2020 Jan;121(1):876-887
pubmed: 31452262
Oncol Res. 2019 Feb 5;27(2):147-155
pubmed: 28800785
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Hum Cell. 2020 Jan;33(1):98-103
pubmed: 31571148
Eur Rev Med Pharmacol Sci. 2015 Dec;19(24):4728-37
pubmed: 26744864
Biomed Pharmacother. 2020 Feb;122:109687
pubmed: 31918267
Cancers (Basel). 2020 Jul 22;12(8):
pubmed: 32707933
Curr Drug Targets. 2019;20(3):302-315
pubmed: 30073924
Oncol Res. 2018 Jul 5;26(6):967-976
pubmed: 29295728
Invest New Drugs. 2018 Aug;36(4):523-535
pubmed: 29460212
Rep Pract Oncol Radiother. 2020 May-Jun;25(3):422-427
pubmed: 32372882
Breast Cancer Res. 2016 Mar 22;18(1):35
pubmed: 27000374
Sci Rep. 2016 Sep 22;6:33823
pubmed: 27654511
Oncotarget. 2016 Aug 9;7(32):52375-52391
pubmed: 27447568